Signals
Microglia Are Not a Shortcut to Alzheimer’s Certainty
Sanofi’s oral TREM2 agonist SAR448851 is moving toward Phase II testing in early Alzheimer’s disease. The mechanism is compelling. The field has already learned that TREM2 biology can disappoint.
BMI is not enough. Cardiometabolic risk is hiding in where fat lives
MS Has Learnt to Stop Inflammation. It Still Cannot Repair the Damage.
Resistant hypertension may need a diagnostic revolution, not just another drug
When diabetes tech fails, personalised care fails with it
For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door
Gonorrhoea Is Not Disappearing. Too Many Systems Are Failing to See It.
Heart pumps save lives. FDA’s latest Impella alerts show why cardiac device safety cannot stop at approval.
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.
Cancer Treatment Is an Endurance Event. Stop Waiting for Patients to Lose Function.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.